内植物及其类型的抗癌潜力
Martina Zigová1, Radka Michalková1, Ján Mojžiš1
1Department of Pharmacology, Faculty of Medicine, Pavol Jozef Šafárik University, 040 01 Košice, Slovakia.
Molecules (Basel, Switzerland)
|May 25, 2024
概括
来自十字花植物的布拉西宁和卡马莱克辛等英多尔植物素显示出抗癌的前景. 新的合成类似物正在开发中,以提高它们对抗癌症的疗效.
科学领域:
- 植物生物化学和药物化学
- 植物防御机制和药理学应用
背景情况:
- 印度类植物素是植物衍生化合物,是十字植物对病原体防御的组成部分.
- 布拉西宁和卡马莱克辛是关键的内醇植物素,具有记录的抗增殖和潜在的抗癌作用.
- 2016年之前的研究集中在这些化合物的抗增殖性质上.
研究的目的:
- 审查布拉西宁和卡马莱克辛的药理作用,强调它们的抗癌潜力.
- 为提供新型合成英多尔植物类同类物的概述.
- 与母化合物相比,评估这些新类型的增强疗效.
主要方法:
- 关于印类植物,布拉西宁和卡马莱克辛的文献综述.
- 对药理学和抗扩散活动的分析.
- 新合成类型的合成和体外试验.
主要成果:
- 布拉西宁和卡马莱克辛具有显著的抗癌特性.
- 新的合成类似物显示出增强的抗扩散活性.
- 印度类植物是一种有前途的癌症治疗化合物.
结论:
- 印度醇植物素具有显著的治疗潜力,特别是在瘤学中.
- 目前正在进行的研究重点是开发更强大的合成类似物来治疗癌症.
- 这些植物性化合物为新型抗癌药物发现提供了宝贵的途径.
更多相关视频
09:33Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
Published on: March 20, 2018
13.8K
09:03Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
Published on: January 26, 2024
348
相关概念视频
Cancer Prevention
6.2K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.2K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Mutagenicity and Carcinogenicity
1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K
